Form 4: Mineralys Therapeutics CEO Jon Congleton Sells Shares Under 10b5-1 Trading Plan

Mineralys Therapeutics CEO Jon Congleton sold 15,746 shares of common stock on July 11, 2024, at a weighted-average price of $13.3415, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 11, 2024, Jon Congleton, the CEO of Mineralys Therapeutics, sold 15,746 shares of the company's common stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on January 30, 2024.
• The shares were sold at a weighted-average price of $13.3415, with individual transaction prices ranging from $12.96 to $13.76.
• Following the transaction, Congleton directly owns 911,212 shares of Mineralys Therapeutics.
• The reporting person has undertaken to provide full information regarding the number of shares sold at each separate price within the specified range upon request.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing an insider stock sale under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Future Outlook

There is no future outlook provided in this document.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It is common for executives to sell shares under pre-arranged 10b5-1 trading plans to avoid accusations of insider trading. The impact on the stock price is usually minimal unless the sale is unusually large or coincides with other negative news.

Stakeholder Impact

• The sale of shares by the CEO could have a minor negative impact on shareholder sentiment, although it is likely to be minimal given the pre-planned nature of the transaction.

Key Dates